HAYWARD, Calif., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel ...

OPMD is a rare progressive muscle-wasting disease caused by a mutation in the poly (A)-binding protein nuclear 1 (PABPN1) gene, for which there is currently no effective drug therapy. The disease is ...